THERAPEUTIC AGENT FOR T CELL MALIGNANCIES

Abstract

A therapeutic agent for a T cell malignancy includes a bispecific antigen-binding molecule including (1) at least one portion that specifically binds to a target tumor antigen expressed on T cell tumor cells, and (2) at least one portion that specifically binds to a normal T cell-side target antigen having subtypes, provided that the target tumor antigen expressed on the T cell tumor cells is either not present on normal T cells, or if present, the normal T cells are not substantially activated when the bispecific antigen-binding molecule binds to the same antigen as the target tumor antigen present on the normal T cells, but binding of the bispecific antigen-binding molecule to the normal T cell-side target antigen activates the normal T cells, and a sufficient proportion of a subtype of the normal T cell-side target antigen is present to provide a sufficient number of activated T cells for the treatment.

CPC Classifications